AKHYNEX

Akhynex is a clinical-stage biotechnology company based in South Korea that focuses on developing next-generation small molecule therapeutics for autoimmune and inflammatory disorders. The company's primary research efforts are centered on highly selective kinase inhibitors, specifically targeting Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1). Its lead candidate, AKX-001, is an orally available TYK2 inhibitor currently undergoing clinical evaluation for the treatment of moderate-to-severe psoriasis and other inflammatory conditions. Akhynex aims to differentiate its pipeline by achieving superior selectivity to minimize the side effects typically associated with broad-spectrum JAK inhibitors, such as those related to JAK2 and JAK3 inhibition. The company leverages a robust medicinal chemistry platform to optimize its drug candidates for improved safety profiles and patient compliance. Founded by industry veterans with experience in global drug development, Akhynex is positioned to address significant unmet needs in the immunology and dermatology markets.